Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.08.27.672581

Predicting Organ-Specific Toxicity of Selective Androgen Receptor Modulators, using Transfer Learning on Graph Convolutional Networks

Abstract

Novel Quantitative Structure-Activity Relationship (QSAR) models were constructed using Graph Convolutional Networks (GCNs), to predict Drug-Induced Liver Injury (DILI), Drug-Induced Renal Injury (DIRI) and Drug-Induced Cardiotoxicity (DICT) of Selective Androgen Receptor Modulators (SARMs) - an emerging class of performance-enhancing drugs. Prior to training on DILI, DIRI and DICT datasets, the GCN QSAR models were first pre-trained on a variety of unrelated biomedical assay datasets, as an attempt to improve model performance via transfer learning. The success of the transfer learning was mixed; model performances were measurably improved via pre-training on certain datasets, by statistically weak increases. The optimal final QSAR models achieved overall accuracy scores of 68% for DILI (no significant improvement via ensemble modelling), 76% for DIRI (improved to 77% via ensemble modelling) and 65% for DICT (improved to 67% via ensemble modelling). Application of the most optimal singular models to a dataset of 25 SARMs predicted that 21 of the 25 SARMs are either DILI-positive, DIRI-positive, or both - which raises concern, given the rising use of SARMs. All SARMs except for one were predicted as DICT-negative. A novel definition of the Applicability Domain (AD) was used, intended for close relevance to the models, via generating three-dimensional graph embeddings, for each model. Convex hulls were fitted around training data embeddings, with a {+/-}10% buffer, defining the AD as the region of embedded chemical space covered by the convex hull, for a given model. Subsequent analysis found that a majority of DILI, DIRI and DICT testing data lay within the AD, alongside a majority of the SARMs - adding consensus to the reliability of the predictions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kalian, A. D., Silva, A. C., Lee, J., Dorne, J.-L. C., Potter, C., Benfenati, E., Osborne, O. J., Guo, M., Hogstrand, C.. 2025-09-01. Predicting Organ-Specific Toxicity of Selective Androgen Receptor Modulators, using Transfer Learning on Graph Convolutional Networks. https://doi.org/10.1101/2025.08.27.672581

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Short-Term Performance Assay Identifies Functional Benefits and Early Toxicity of Longevity Interventions in Mice

Mouse lifespan studies are slow and costly, limiting the number of interventions that have demonstrated robust anti-aging effects. This highlights the need for rapid early-stage screening tools capable of assessing both efficacy and potential side effects. Here, we present a short-term performance assay designed to rapidly profile functional benefits and early toxicity of longevity interventions in mice. Over an 8-week period, mice received one of five candidate anti-aging treatments: 17-estradiol, rapamycin + Smer28, berberine + resveratrol, sildenafil and pinealon. The protocol longitudinally monitored body weight and temperature, and food intake, alongside post-treatment assessments of grip strength, locomotor activity, Y-maze cognition, social behavior, and hematological and urinary parameters. The screen revealed compound-specific phenotypes: 17-estradiol induced significant weight loss, increased grip strength, and dorsal alopecia, consistent with metabolic remodeling. Sildenafil reduced basal body temperature and preserved locomotor activity. Berberine + resveratrol decreased food intake and fasting glucose without major changes in physical performance, resembling caloric restriction-like metabolic effects. Rapamycin + Smer28 modestly improved strength and sociability but induced anemia in 2 of 5 mice, indicating potential dose-dependent toxicity. Pinealon showed a trend toward improved working memory without detectable adverse effects. This multi-parametric approach enables discover healthspan extending interventions facilitating prioritization and dose refinement before committing to full lifespan studies. Finally, to our knowledge, this represents the first comprehensive preclinical aging study in mice fully funded through tokenized decentralized science (DeSci), demonstrating how community-governed, on-chain funding can support resource-intensive in vivo research.

pharmacology and toxicology↗